European IBD market is estimated to grow significantly at a CAGR of around 5.1% during the forecast period. Europe consists of numerous key economies including the UK, Germany, France, Spain, Italy, and others which register a significant share in the market. The changing lifestyle and significant share of the population which engages in smoking is also one of the key reasons which are expected to increase the prevalence of IBD in the region. The European Federation of Crohn's & Ulcerative Colitis Associations is one such organization in the region which engages in the monitoring of IBD and conducting clinical studies so as to develop an efficient treatment alternative for IBD. Furthermore, the prevalence of IBD increases with a change in eating patterns and unhealthy eating and smoking practices. It is observed that smoking is one of the key reasons which promotes the prevalence of IBD in the working-age population. The percentage of population smoking in the UK is majorly between the age group of 25-34. Owing to this, the prevalence of IBD is expected to increase, thereby creating opportunities for the growth of the market in the near future.

Request a Free Sample of our European Inflammatory Bowel Disease (IBD) Market: https://www.omrglobal.com/request-sample/european-ibd-inflammatory-bowel-disease-market

European IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. European IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market is segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

A full Report of European Inflammatory Bowel Disease (IBD) Market is Available at: https://www.omrglobal.com/industry-reports/european-ibd-inflammatory-bowel-disease-market

European IBD Inflammatory Bowel Disease Market Segmentation

By Disease Type

• Ulcerative Colitis
• Crohn’s Disease

By Diagnostics

• Blood and Stool Tests
• Endoscopies,
• Ultrasound
• X-Ray

By Therapeutics

• Surgery
• Anti- Inflammatory Drug Administration
• Steroids
• Immunosuppressant
• Biological Drugs
• Amino salicylates
• Others

Regional Analysis

• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Company Profiles

• AbbVie Inc.
• Allergan, PLC
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Pharmacosmos A/S
• Sanofi S.A.
• Takeda pharmaceutical Co., Ltd.
• UCB, Inc.
• Vifor Pharma Group

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-ibd-inflammatory-bowel-disease-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404